- Integrating the expertise and capabilities of both companies for efficient clinical trial solutions
(From the left) Moon Hanlim, CEO of MediRama, and Cho Kwan-goo, CEO of GCCL (Source: GCCL)
GCCL, a global clinical trial sample analysis agency, announced on May 13 that it entered into a memorandum of understanding (MOU) with MediRama on May 12, aimed at fostering mutual cooperation in clinical trial services.
The signing ceremony, held at MediRama’s headquarters, was attended by key representatives from both companies, including MediRama CEO Moon Hanlim and GCCL CEO Cho Kwan-goo. During the event, the two companies reaffirmed their commitment to collaboration, discussing the direction of potential cooperation in various areas, including clinical trial services, technology exchange, and joint business planning. Additionally, they emphasized their shared intention to support Korean and international novel drug developers throughout the entire clinical development process, from strategic planning to the generation of analytical data.
The key contents of the business agreement include joint cooperation in clinical service businesses for novel drug development, cooperation in the consignment and execution of domestic and international clinical trial services, planning and marketing of joint business initiatives, mutual exchange of technological and academic information, and other areas of mutual interest based on the needs of both parties.
GCCL and MediRama anticipate that by combining their respective strengths and expertise in the clinical trial service sector, they will enhance their competitiveness in both Korean and global clinical development markets, generating synergy for more rapid and precise clinical outcomes. In particular, the integration of MediRama’s strategic clinical development know-how and GCCL’s specialized capabilities in precise sample analysis is expected to provide more efficient clinical trial solutions to their clients.
“With this agreement, we expect to create a more stable and efficient clinical development environment by effectively integrating the strengths of both companies,” said Moon Hanlim, CEO of MediRama. “We will maintain close collaboration with GCCL to further strengthen our competitiveness in the domestic and international clinical trial markets,” she added.
“Establishing a cooperative model with MediRama that supports the entire new drug development cycle based on precise and reliable analysis services is meaningful,” expressed Cho Kwan-goo, CEO of GCCL. “Through this agreement, we aim to maximize mutual synergy and set a new benchmark for delivering faster and more reliable clinical services to the clients of both companies.”
Founded in 2021, MediRama is a clinical development company recognized for its expertise in anticancer drug development. The company currently operates its proprietary ‘ABCD (Advanced Business Model for Clinical Development) platform,’ a comprehensive one-stop solution that efficiently supports the entire clinical trial process. This platform covers all aspects of clinical development, from strategy formulation and trial execution to issue resolution and real-time response management, providing rapid and precise support throughout the development cycle. MediRama currently serves as the clinical development headquarters for various biotechnology companies, supporting their successful clinical development.
GCCL is a clinical trial specimen analysis institution certified in all fields of Good Clinical Laboratory Practice (GCLP) by the Ministry of Food and Drug Safety. The company provides tailored clinical analysis services throughout the entire clinical trial cycle, from Phase 1 to Phase 4, aligning with global standards. Leveraging a range of analytical platforms, including the introduction of ddPCR devices, and offering specialized specimen analysis and method development services, GCCL supports clinical trial specimen analysis needs for Korean pharmaceutical and biotech companies, as well as partners across the Asian region and around the world.*Links:
The BIO, Yu, Suin, GCCL and MediRama sign MOU for strategic collaboration in clinical trial services
> About GCCL > Newsroom > Press Release